Gannex Pharma, a subsidiary of Hangzhou's Ascletis Pharma, partnered with Israel 's Galmed Pharma to test a combination of ASC41 and Galmed's Aramchol (SCD 1 inhibitor) to treat non-alcoholic steatohepatitis (NASH). Gannex's ASC41 is an oral thyroid hormone receptor beta (THR-beta) agonist that was recently approved to begin China clinical trials for NASH. The company expects to provide topline results from a Phase I trial by the end of 2020. Financial details of the transaction were not disclosed. More details.... Stock Symbols: (HK: 1672) (NSDQ: GLMD) Share this with colleagues: // //